In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.06, marking a -5.72% move from the previous day.
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.31, indicating a +1.96% shift from the previous trading day.
Ginkgo Bioworks Holdings, Inc. ( DNA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting Officer & CFO Presentation Daniel Waid Marshall [Audio Gap] Manager of Communications and Ownership at Ginkgo. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Coen, our CFO.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $12.74, signifying a -4.85% move from its prior day's close.
Ginkgo Bioworks Holdings, Inc. (DNA) reached $15.24 at the closing of the latest trading day, reflecting a -5.28% change compared to its last close.
After reaching an important support level, Ginkgo Bioworks Holdings, Inc. (DNA) could be a good stock pick from a technical perspective. DNA surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason Kelly - Founder, CEO & Director Steven P. Coen - Chief Accounting Officer & CFO Daniel Waid Marshall Good evening.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $13.96, signifying a -6.31% move from its prior day's close.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.6, signifying a +1.8% move from its prior day's close.
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $10.79, denoting a -2.53% move from the preceding trading day.
Ginkgo Bioworks (DNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Regeneron said it will continue uninterrupted service of 23andMe's consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the third quarter of this year.